$LMB

Horowitz Joshua purchased $60K of LMB

Horowitz Joshua purchased 1,212 shares of Limbach Holdings, Inc. (LMB) at an average of $49.78 ($49.59–$50.66) across 2 trades over 2026-09-11 to 2026-09-15. Filed jointly with Palm Global Small Cap Master Fund LP.

Original reporting
SEC EDGAR · Horowitz Joshua, Palm Global Small Cap Master Fund LP
Published Sep 15, 2026, 11:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LMB
Neutral
low confidence
Mentioned
$LMB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LMBNeutralLow
01

Why it matters

The filing provides the first public record of the director's recent share purchase.

02

Market read

Minor insider buy; unlikely to move the stock materially.

03

What to watch

Potential upcoming corporate actions not disclosed may influence insider behavior.

Relevance 4/10Novelty 4/10Timing: filing today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$LMBNeutralLow confidence
Context

Director Horowitz Joshua bought 1,212 shares for $60.3K, increasing his stake to 43,997 shares.

Expected impact

Minimal price movement expected.

Evidence & confidence

Purchase size is modest relative to float; typical for micro‑cap insiders.

Market effects

None significant for sector.

Limited to company level.

None

Counterpoint

Insider purchase could be a routine portfolio adjustment, not a strong bullish signal.

Key entities

  • Limbach Holdings, Inc.

    Issuer of the Form 4.

  • Horowitz Joshua

    Director and insider purchaser.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LMBMed

JPMorgan downgrades Limbach stock rating on valuation concerns

JPMorgan downgraded Limbach Holdings (LMB) to Underweight, lowering its price target to $50 from $60. The stock is near its 52-week low at $42.75. Five analysts revised earnings downward. The company reported Q2 2026 earnings and revenue below expectations, with near-term margin pressures cited. Stifel lowered its price target to $86 but maintained a Buy rating.

$LMBMedAI 8/10

Why Limbach Is Buying CYMCOR For $30 Million

Limbach Holdings said it acquired CYMCOR for about $30 million to expand in data center infrastructure services. The deal, funded via cash and borrowings under its revolving credit facility, is expected to add about $12 million of professional services revenue and $4 million of adjusted EBITDA in 2027. CYMCOR manages projects with over $8 billion in budgets.

$LMBMedAI 8/10

Read Analyst Questions From Limbach’s Q2 Earnings Call

Limbach (LMB) reported Q2 revenue of $173.5M, below analysts’ $177.3M estimate, and adjusted EPS of $0.64 versus $0.93 expected. Adjusted EBITDA was $13.94M versus $19.6M expected, with operating margin at 4.3%. CEO Michael McCann cited project timing and softer healthcare and institutional demand. Full-year revenue guidance was raised to $775M midpoint, but EBITDA guidance was below estimates.

$LMBMedAI 8/10

Limbach Q2 Earnings Call Highlights

Limbach Holdings (NASDAQ: LMB) reported Q2 revenue up 35.3% to $45 million, with organic GCR revenue up 12% and acquisition-related revenue up 23.3%. Gross margin fell to 21.5% from 28%, and net income dropped 38.8% to $4.7 million. Operating cash flow rose to $18.7 million. The company raised 2026 revenue guidance to $760M-$790M and lowered adjusted EBITDA to $78M-$84M.

$LMBHighAI 9/10

Why Limbach (LMB) Stock Is Nosediving

Limbach (LMB) shares fell 31.5% after the company reported mixed Q2 2026 results and guidance below expectations. Revenue was $173.5M vs $177.3M consensus. Adjusted EPS was $0.64, 30.9% below forecasts. Full-year revenue guidance rose, but EBITDA guidance of $81M missed Wall Street.